PPT-Ibrutinib for Hairy Cell Leukemia

A Brief Update of an Ongoing Trial Jeff Jones MD MPH 16 May 2015 2 P LYN BCR CD79a CD79b SYK BTK PLC γ IBRUTINIB GROWTH SURVIVAL Bcell Receptor is the Accelerator of Bcells. New agents timing?. Agne Paner, MD. Assistant professor of Medicine. RUSH University Medical Center. Blood Smear in CLL. Chronic Lymphocytic Leukemia. Most prevalent type of adult leukemia . 30% of all . What I Know About Hairy- Eared . D. warf . L. emurs!. 1. Lemurs . were found in 1989 . in northeastern Madagascar.. . The length of adults is 5.31 inches, and weighs up to a ¼ OF A POUND. Its fur is brownish gray in color with whitish underparts, and it has a reddish brown tail.. Mary E. MacBlane MS, PNP-BC. Goals. Incidence. Etiology. Diagnosis. Types/Classification. Treatment. Primary Care Pearls. Incidence. 30% of all cancers in childhood. Peak incidence 2-5 years of age. males > females. RESONATE . (PCYC-1112) Trial of Ibrutinib Compared With Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Paul M. Barr, John C. Byrd,. . Jennifer . R. Brown. Jung/. Shlush. Department . of Immunology. . Objectives of the seminar. Learn about the newest research the . . . hematopoetic. system and leukemia. Identify emerging topics and techniques. Overview. Overview (cont). Ibrutinib. -R. elated Cardiovascular A. E. s. Atrial Fibrillation. Ibrutinib-Related AF Data From 2016 ASH Conference. Wiczer et al Data. Risk Stratification. . Mechanisms of Ibrutinib-Related Cardiotoxicity. Forms a specific and irreversible bond with cysteine-481 in BTK. Highly potent BTK inhibition at . IC. 50. = 0.5 . nM. Orally administered with once daily dosing resulting in 24-hr target inhibition. Simon Rule. Professor of Clinical . Haematology. Consultant . Haematologist. Derriford. Hospital and Peninsula Medical School Plymouth. DISCLOSURES OF COMMERCIAL SUPPORT. Name of Company. Research support. Shira . Dinner, MD. Northwestern University. Educational Objectives. Define terminology used regarding leukemia. Describe . the latest developments in . the treatment of acute . lymphoblastic leukemia (ALL). 45 KEYWORDS Letterer-Siwe disease, chronic myelomonocytic leukemiaUMMARY Introduction 46 Case reportsLetterer-Siwe disease and chronic myelomyonocytic leukemiaActa Dermatoven APA Vol 19, 2010, No 1 re Evolving Treatment Strategies. for CLL/SLL and MCL. Beth Faiman PhD, MSN, APRN-BC, AOCN. Nurse Practitioner. Department of Hematology and Medical Oncology. Cleveland Clinic Taussig Cancer Institute. Cleveland, Ohio. Josie . Montegaard. , MSN, AGPCNP-BC. Matthew S . Davids. , MD, . MMSc. . Disclosures for . Ms. . Montegaard. Advisory Committee . Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company . Consulting Agreements . Introduction to Leukemia. Definition. Historic Perspective. Etiology and Risk Factors . Incidence. Classification. Comparison of Acute and Chronic Leukemia. Leukemia. Definition. Leukemia is a malignant disease of hematopoietic tissue characterized by the accumulation abnormal white cells (neoplastic or leukemic) in the bone marrow leading to bone marrow failure, a raised circulating white cell count (leukocytosis) and infiltrate organs (e.g liver, spleen, lymph nodes, brain) . Kelsey Shaffer. CHTN. Staff Meeting Presentation. What is it?. Acute Lymphoblastic Leukemia (ALL) is a blood cancer. White Blood Cells (WBC). Lymphocytes or Lymphoblast . Too many immature WBC. Crowd the bone marrow.